Journal of Clinical Oncology, Vol 13, 2317-2323, Copyright © 1995 by American Society of Clinical Oncology

ARTICLES

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer

M Hill, A Norman, D Cunningham, M Findlay, M Watson, V Nicolson, A Webb, G Middleton, F Ahmed and T Hickish
Cancer Research Campaign, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

PURPOSE: The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer. PATIENTS AND METHODS: Patients who attended our unit with histologically confirmed advanced colorectal cancer were randomized to receive either PVI 5-FU 300 mg/m2/d via Hickman line, and IFN 5 MU subcutaneously three times weekly, or PVI 5-FU alone. Treatment was given for a maximum of two 10-week blocks, with a 2-week gap for reassessment of all parameters. Quality of life (QL) was measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) pretreatment and every 6 weeks thereafter. RESULTS: A total of 160 patients were randomized, with 155 eligible for assessment. Radiologic response was observed in 43 patients (28%): 17 of 77 (22%) in the 5-FU- plus-IFN arm (all partial responses [PRs]) and 26 of 78 (33%) in the 5- FU-alone group (complete responses [CRs] and 22 PRs) (difference not significant). Symptomatic improvement occurred in the majority of patients, and equally in both arms: 61% to 80% depending on the symptom. There was no significant difference between the two groups in failure-free survival (median, 161 v 193 days) or overall survival (median, 328 v 357 days). However, patients who received IFN did experience significantly more toxicity in the form of leukopenia (P = .001), neutropenia (P = .04), mucositis (P = .008), and alopecia (P = .0002). There were no toxic deaths and few notable differences in QL between the two arms. CONCLUSION: This study confirms that PVI 5-FU is effective in treating the symptoms associated with metastatic colorectal carcinoma, with only mild to moderate toxicity and maintenance of QL. IFN 5 MU three times weekly does not enhance these palliative benefits.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. V. Negri, A. Wotherspoon, D. Cunningham, A. R. Norman, G. Chong, and P. J. Ross Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer Ann. Onc., August 1, 2005; 16(8): 1305 - 1310. [Abstract] [Full Text] [PDF]

				D. Provenzale and R. N. Gray Colorectal Cancer Screening and Treatment: Review of Outcomes Research J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 45 - 55. [Abstract] [Full Text] [PDF]

				G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials Ann. Onc., September 1, 2004; 15(9): 1330 - 1338. [Abstract] [Full Text] [PDF]

				C. Gennatas, C. Dardoufas, D. Mouratidou, N. Tsavaris, A. Pouli, G. Androulakis, M. Philippakis, D. Voros, T. Batalis, S. Besbeas, et al. Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-{alpha}2b Ann. Onc., March 1, 2003; 14(3): 378 - 382. [Abstract] [Full Text] [PDF]

				C.-H. Kohne, D. Cunningham, F. Di Costanzo, B. Glimelius, G. Blijham, E. Aranda, W. Scheithauer, P. Rougier, M. Palmer, J. Wils, et al. Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients Ann. Onc., February 20, 2002; 13(2): 308 - 317. [Abstract] [Full Text] [PDF]

				D. Papamichael The Use of Thymidylate Synthase Inhibitors in the Treatment of Advanced Colorectal Cancer: Current Status Oncologist, December 1, 1999; 4(6): 478 - 487. [Abstract] [Full Text]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				J. D. Shapiro, N. Harold, C. Takimoto, J. M. Hamilton, D. Vaughn, A. Chen, S. M. Steinberg, D. Liewehr, C. Allegra, B. Monahan, et al. A Pilot Study of Interferon {{alpha}}-2a, Fluorouracil, and Leucovorin Given with Granulocyte-Macrophage Colony Stimulating Factor in Advanced Gastrointestinal Adenocarcinoma Clin. Cancer Res., September 1, 1999; 5(9): 2399 - 2408. [Abstract] [Full Text] [PDF]

				P. M. Hoff and R. Pazdur UFT Plus Oral Leucovorin: A New Oral Treatment for Colorectal Cancer Oncologist, June 1, 1998; 3(3): 155 - 164. [Abstract] [Full Text]